Temodal 100 mg hard capsules
Sponsors
Inhibrx Biosciences Inc., TME Pharma AG, Laminar Pharmaceuticals S.A., Institut Gustave Roussy
Conditions
Advanced or metastatic solid tumorsGlioblastomaNewly diagnosed primary glioblastoma multiforme (ndGBM)Pancreatic NeuroEndocrine Tumors (PanNET) ; Aggressive stage I-III well differentiated R0 resectedPatients with High Risk Neuroblastoma
Phase 1
Single-arm dose-escalation Phase 1/2 study of olaptesed pegol (NOX-A12) in combination with irradiation in inoperable or partially resected first-line glioblastoma patients with unmethylated MGMT promoter with a multiple-arm expansion group
RecruitingCTIS2024-510964-21-00
Start: 2019-09-12Target: 136Updated: 2025-11-18
An Open-Label, Multicenter, First-in-Human, Phase 1 Dose Escalation and Multicohort Expansion Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors, Including Sarcomas.
RecruitingCTIS2023-508139-29-00
Start: 2024-06-26Target: 37Updated: 2025-10-09
Phase 2
Phase 3
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) “Randomized, international and multicentric phase 3 study that evaluates and compares 2 treatment strategies in 3 therapeutic phases (induction, high-dose chemotherapy and radiotherapy) for patients with high-risk neuroblastoma and introduces chemoimmunotherapy for patients with insufficient metastatic response after induction chemotherapy
RecruitingCTIS2024-514917-36-00
Start: 2024-11-21Target: 719Updated: 2025-01-17
First adjuvant trial in locally resected aggressive pancreatic neuroendocrine tumors: a randomized phase III investigating the efficacy of systemic chemotherapy (ADJUPANET)
Not yet recruitingCTIS2025-523593-16-00
Target: 504Updated: 2026-06-10